ENvue Medical, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ENvue Medical, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $318.0K | May 13, 2019 |
| FY2018 | Dec 31, 2017 | $239.0K | May 13, 2019 |
| FY2017 | Dec 31, 2016 | $229.0K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $147.0K | Jul 26, 2017 |
| FY2015 | Dec 31, 2014 | $203.0K | Mar 30, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.55M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $2.56M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.28M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $752.0K | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | $1.70M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $623.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $530.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $318.0K | May 20, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $153.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.51M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.54M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $167.0K | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | $770.0K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $214.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $281.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $160.0K | May 20, 2020 |
| FY2018 | Dec 31, 2017 | $151.0K | May 13, 2019 |
| FY2017 | Dec 31, 2016 | $141.0K | Mar 29, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.19M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($3.71M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($3.71M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.45M) | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | ($14.28M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($4.33M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($5.79M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($4.15M) | May 20, 2020 |
| FY2018 | Dec 31, 2017 | ($4.97M) | May 13, 2019 |
| FY2017 | Dec 31, 2016 | ($2.83M) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.89M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($3.58M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($3.44M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.01M) | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | ($5.68M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($4.72M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($5.15M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($4.30M) | May 20, 2020 |
| FY2018 | Dec 31, 2017 | ($3.09M) | May 13, 2019 |
| FY2017 | Dec 31, 2016 | ($2.32M) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.76M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $909.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $185.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $283.0K | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | $293.0K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $171.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $514.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $614.0K | May 20, 2020 |
| FY2018 | Dec 31, 2017 | $693.0K | May 13, 2019 |
| FY2017 | Dec 31, 2016 | $584.0K | Mar 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.37M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($2.52M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($3.60M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.04M) | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | ($4.37M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($3.39M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($3.87M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($3.55M) | May 20, 2020 |
| FY2018 | Dec 31, 2017 | ($2.18M) | May 13, 2019 |
| FY2017 | Dec 31, 2016 | ($1.53M) | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.0K | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | $3.0K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.0K | Apr 15, 2022 |
| FY2019 | Dec 31, 2018 | $8.0K | May 20, 2020 |
| FY2017 | Dec 31, 2016 | $8.0K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $1.0K | Jul 26, 2017 |
| FY2015 | Dec 31, 2014 | $4.0K | Mar 30, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.12M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.63M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $6.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.88M | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | $8.62M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $8.23M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.04M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $1.58M | May 20, 2020 |
| FY2018 | Dec 31, 2017 | $4.87M | May 13, 2019 |
| FY2017 | Dec 31, 2016 | $494.0K | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.63M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.00M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.69M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.65M | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | $2.31M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $5.84M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $688.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $1.12M | May 20, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.50M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $627.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $3.99M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $3.23M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $6.31M | Apr 8, 2024 |
| FY2022 | Dec 31, 2020 | $2.39M | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | $1.35M | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | $463.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | $3.63M | May 20, 2020 |
| FY2017 | Dec 31, 2016 | ($2.50M) | Mar 29, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.08M | Apr 15, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($90.48M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($69.80M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($66.10M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($62.39M) | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | ($56.94M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($42.66M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($38.33M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($32.54M) | May 20, 2020 |
| FY2018 | Dec 31, 2017 | ($28.38M) | May 13, 2019 |
| FY2017 | Dec 31, 2016 | ($22.58M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.22M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $752.0K | Apr 15, 2026 |
| FY2021 | Dec 31, 2021 | $7.74M | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $7.14M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.34M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $896.0K | May 20, 2020 |
| FY2018 | Dec 31, 2017 | $4.36M | May 13, 2019 |
| FY2018 | Dec 31, 2016 | $106.0K | May 13, 2019 |
| FY2017 | Dec 31, 2015 | $1.61M | Mar 29, 2018 |
| FY2016 | Dec 31, 2014 | $90.0K | Jul 26, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (26) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (137) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (23) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | (11) | Apr 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (26) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (137) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (23) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Apr 8, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.10M | Apr 15, 2026 |
| FY2025 | Aug 11, 2025 | 10 | Apr 15, 2026 |
| FY2025 | Mar 13, 2025 | 11 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 37,894 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 186,028 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 1.64M | Apr 8, 2024 |
| FY2022 | Dec 31, 2021 | 1.40M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 21.25M | Apr 15, 2022 |
| FY2021 | Dec 3, 2020 | 19.85M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 4.20M | Apr 15, 2021 |